Prostate Cell News 10.01 January 18, 2019 | |
| |
TOP STORYLEADeR Role of miR-205 Host Gene as Long Noncoding RNA in Prostate Basal Cell Differentiation Scientists showed that only lowly expressed alternatively spliced MIR205HG transcripts act as de facto pri-miRNAs, through a process that involves Drosha to prevent unfavorable splicing and directly mediate miR-205 excision. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)ONECUT2 Is a Driver of Neuroendocrine Prostate Cancer ONECUT2 ectopic expression in prostate adenocarcinoma synergized with hypoxia to suppress androgen signaling and induce neuroendocrine plasticity. ONECUT2 drove tumor aggressiveness in neuroendocrine prostate cancer, partially through regulating hypoxia signaling and tumor hypoxia. [Nat Commun] Full Article Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity Using cancer stem cell (CSC)-like cell models isolated from clinical biopsy tissues, scientists identified the E3 ligase MDM2 as a key regulator of prostate CSC integrity. [Cancer Res] Abstract The authors demonstrated 100-fold heterogeneity in androgen receptor (AR) output within human prostate cancer cell lines and showed that cells with high AR output have reduced sensitivity to enzalutamide. [eLife] Full Article Polycomb Group Proteins EZH2 and EED directly Regulate Androgen Receptor in Advanced Prostate Cancer Researchers report that enhancer of zeste homolog 2 (EZH2) and embryonic ectoderm development (EED) indicate respective direct interaction with androgen receptor (AR). In the context of AR‐positive prostate cancer, EZH2 and EED regulated AR expression levels and AR downstream targets. [Int J Cancer] Abstract ARD-69 induced degradation of androgen receptor (AR) protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. [J Med Chem] Abstract | Graphical Abstract Chemical‐based medicine that targets specific oncogenes or proteins often leads to cancer recurrence due to tumor heterogeneity and development of chemoresistance. This challenge can be overcome by mechanochemical disruption of cancer cells via focused ultrasound and sensitizing chemical agents such as ethanol. Investigators demonstrated that this disruptive therapy decreased the viability, proliferation rate, tumorigenicity, endothelial adhesion, and migratory ability of prostate cancer cells in vitro. [Mol Cancer Res] Abstract A negative correlation was observed between methylation and UNC5D mRNA expression in prostate cancer (PCa) samples. The ectopic expression of UNC5D in PCa cells effectively reduced their ability to migrate and invade both in vitro and in vivo, and siRNA‐mediated knockdown of UNC5D yielded consistent results. [Cancer Sci] Abstract In vitro, GHET1 siRNA was used to investigate the biological role of GHET1 in prostate cancer cell lines. Cell proliferation was detected by CCK‐8 and colony formation assay, while cell cycle and cell apoptosis were analyzed using flow cytometry. [Biofactors] Abstract Scientists explored the effects of a glucosamine derivative, 2-(N-Carbobenzyloxy)l-phenylalanylamido-2-deoxy-β-d-glucose, on two prostate cancer cell lines, PC3 and LNCaP. [Chem Biol Interact] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSApproaches to Urinary Detection of Prostate Cancer The authors provide a review of current literature on urinary biomarkers for prostate cancer. [Prostate Cancer Prostatic Dis] Abstract The Anticancer Potential of Metformin on Prostate Cancer Scientists review the literature regarding the numerous mechanisms of action of metformin on prostate cancer (PCa) in order to decrease or repress the growth, proliferation, and differentiation of PCa cells. [Prostate Cancer Prostatic Dis] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSLeap Therapeutics, Inc. announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01, as a monotherapy and in combination with docetaxel in patients with advanced prostate cancer. [Leap Therapeutics, Inc.] Press Release The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has granted marketing authorization for ERLEADA®, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease. [Janssen (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSCrash-Out Brexit Looms Larger for Scientists after Deal Rejected A historic defeat for U.K. Prime Minister Theresa May has raised the odds that the United Kingdom will crash out of the European Union in March, a prospect that scientists dread for its potential for disruption to research collaborations and the economy. [ScienceInsider] Editorial German Institutions and Wiley Reach Open-Access Publishing Deal Ater nearly three years of contract negotiations, a consortium of nearly 700 German libraries, research institutes, and universities called Project DEAL has forged an agreement with the scholarly publisher Wiley that moves the publishing industry towards more open access. [The Scientist] Editorial How UK Scientists Are Planning for a Chaotic No-Deal Brexit British scientists are ramping up preparations for a ‘no deal’ Brexit on 29 March — a situation that would instantly affect travel, data collection, clinical trials and crucial laboratory supplies. [Nature News] Editorial
| |
EVENTSNEW European CanCer Organisation (ECCO) 2019: European Cancer Summit Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Prostate Cancer (University of Glasgow) NEW PhD Student – Oncolytic Virus Immune Therapy (German Cancer Research Center) Postdoctoral Research Assistant – Prostate Cancer (AstraZeneca) Senior Research Assistant – Cancer Biology (MD Anderson Cancer Center) Faculty Position – Radiation Oncology & Molecular Radiation Sciences (Johns Hopkins University) Research Fellow – Prostate Cancer Pathology (Weill Cornell Medicine) Tenure-Track/Tenured Faculty Positions – Cancer Biology (University of Chicago) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|